select a format

Single User License
USD 2000 INR 130060
Site License
USD 4000 INR 260120
Corporate User License
USD 6000 INR 390180

Alternatively

Request a quote
Request a Customized research
Request for Sample Report

NEWSLETTER BY CATEGORY




Recent Viewed Reports


Why Ken Reasearch?


Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"


Malignant Mesothelioma-Pipeline Review, H2 2017

Malignant Mesothelioma-Pipeline Review, H2 2017


  • Products Id :- GMDHC9702IDB
  • |
  • Pages: 547
  • |
  • September 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Malignant Mesothelioma-Pipeline Review, H2 2017, provides an overview of the Malignant Mesothelioma (Oncology) pipeline landscape.
Malignant pleural mesothelioma is a rare cancer often diagnosed in people who have been exposed to high levels of asbestos. The malignancy affects the pleura, a thin membrane of lubricating cells that lines the lungs and chest wall. Peritoneal mesothelioma originates in the abdomen and as a result, symptoms often include abdominal pain, weight loss, nausea, and vomiting. Other symptoms include anemia, bowel obstructions, chest pain and hemoptysis.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Malignant Mesothelioma-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Malignant Mesothelioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Malignant Mesothelioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Malignant Mesothelioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 4, 34, 25, 15, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 3, 6 and 6 molecules, respectively.
Malignant Mesothelioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The pipeline guide provides a snapshot of the global therapeutic landscape of Malignant Mesothelioma (Oncology).
The pipeline guide reviews pipeline therapeutics for Malignant Mesothelioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Malignant Mesothelioma (Oncology) therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Malignant Mesothelioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Malignant Mesothelioma (Oncology)
Reasons to buy
Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
Find and recognize significant and varied types of therapeutics under development for Malignant Mesothelioma (Oncology).
Classify potential new clients or partners in the target demographic.
Develop tactical initiatives by understanding the focus areas of leading companies.
Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
Formulate corrective measures for pipeline projects by understanding Malignant Mesothelioma (Oncology) pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

Introduction 5

Malignant Mesothelioma-Overview 6

Malignant Mesothelioma-Therapeutics Development 7

Malignant Mesothelioma-Therapeutics Assessment 20

Malignant Mesothelioma-Companies Involved in Therapeutics Development 33

Malignant Mesothelioma-Drug Profiles 60

Malignant Mesothelioma-Dormant Projects 521

Malignant Mesothelioma-Discontinued Products 523

Malignant Mesothelioma-Product Development Milestones 524

Appendix 536

List of Figures

Number of Products under Development for Malignant Mesothelioma, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Top 10 Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

List of Tables

Number of Products under Development for Malignant Mesothelioma, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Malignant Mesothelioma-Pipeline by Aduro BioTech Inc, H2 2017

Malignant Mesothelioma-Pipeline by Advantagene Inc, H2 2017

Malignant Mesothelioma-Pipeline by AnGes MG Inc, H2 2017

Malignant Mesothelioma-Pipeline by arGEN-X BV, H2 2017

Malignant Mesothelioma-Pipeline by ArQule Inc, H2 2017

Malignant Mesothelioma-Pipeline by AVEO Pharmaceuticals Inc, H2 2017

Malignant Mesothelioma-Pipeline by Biogen Inc, H2 2017

Malignant Mesothelioma-Pipeline by Bionomics Ltd, H2 2017

Malignant Mesothelioma-Pipeline by Biotecnol Ltd, H2 2017

Malignant Mesothelioma-Pipeline by Boehringer Ingelheim GmbH, H2 2017

Malignant Mesothelioma-Pipeline by Boston Biomedical Inc, H2 2017

Malignant Mesothelioma-Pipeline by Bristol-Myers Squibb Company, H2 2017

Malignant Mesothelioma-Pipeline by Calithera Biosciences Inc, H2 2017

Malignant Mesothelioma-Pipeline by CanBas Co Ltd, H2 2017

Malignant Mesothelioma-Pipeline by CBT Pharmaceuticals Inc, H2 2017

Malignant Mesothelioma-Pipeline by Checkpoint Therapeutics Inc, H2 2017

Malignant Mesothelioma-Pipeline by Concordia International Corp, H2 2017

Malignant Mesothelioma-Pipeline by Eagle Pharmaceuticals Inc, H2 2017

Malignant Mesothelioma-Pipeline by Eli Lilly and Company, H2 2017

Malignant Mesothelioma-Pipeline by EnGeneIC Ltd, H2 2017

Malignant Mesothelioma-Pipeline by EpiZyme Inc, H2 2017

Malignant Mesothelioma-Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Malignant Mesothelioma-Pipeline by Five Prime Therapeutics Inc, H2 2017

Malignant Mesothelioma-Pipeline by Genelux Corp, H2 2017

Malignant Mesothelioma-Pipeline by GlaxoSmithKline Plc, H2 2017

Malignant Mesothelioma-Pipeline by Horizon Pharma Plc, H2 2017

Malignant Mesothelioma-Pipeline by Inventiva, H2 2017

Malignant Mesothelioma-Pipeline by Juno Therapeutics Inc, H2 2017

Malignant Mesothelioma-Pipeline by Karyopharm Therapeutics Inc, H2 2017

Malignant Mesothelioma-Pipeline by Laboratoires Pierre Fabre SA, H2 2017

Malignant Mesothelioma-Pipeline by MacroGenics Inc, H2 2017

Malignant Mesothelioma-Pipeline by Madrigal Pharmaceuticals Inc., H2 2017

Malignant Mesothelioma-Pipeline by MedImmune LLC, H2 2017

Malignant Mesothelioma-Pipeline by Merck & Co Inc, H2 2017

Malignant Mesothelioma-Pipeline by Merck KGaA, H2 2017

Malignant Mesothelioma-Pipeline by Millennium Pharmaceuticals Inc, H2 2017

Malignant Mesothelioma-Pipeline by MolMed SpA, H2 2017

Malignant Mesothelioma-Pipeline by Morphotek Inc, H2 2017

Malignant Mesothelioma-Pipeline by MTG Biotherapeutics Inc, H2 2017

Malignant Mesothelioma-Pipeline by Novartis AG, H2 2017

Malignant Mesothelioma-Pipeline by Ono Pharmaceutical Co Ltd, H2 2017

Malignant Mesothelioma-Pipeline by OSE Immunotherapeutics, H2 2017

Malignant Mesothelioma-Pipeline by Oxford BioMedica Plc, H2 2017

Malignant Mesothelioma-Pipeline by Pharma Mar SA, H2 2017

Malignant Mesothelioma-Pipeline by Philogen SpA, H2 2017

Malignant Mesothelioma-Pipeline by Polaris Pharmaceuticals Inc, H2 2017

Malignant Mesothelioma-Pipeline by Seattle Genetics Inc, H2 2017

Malignant Mesothelioma-Pipeline by Selecta Biosciences Inc, H2 2017

Malignant Mesothelioma-Pipeline by Sorrento Therapeutics Inc, H2 2017

Malignant Mesothelioma-Pipeline by Targovax ASA, H2 2017

Malignant Mesothelioma-Pipeline by Tesaro Inc, H2 2017

Malignant Mesothelioma-Pipeline by TRACON Pharmaceuticals Inc, H2 2017

Malignant Mesothelioma-Pipeline by TREAT U SA, H2 2017

Malignant Mesothelioma-Pipeline by UbiVac LLC, H2 2017

Malignant Mesothelioma-Pipeline by VasGene Therapeutics Inc, H2 2017

Malignant Mesothelioma-Pipeline by Verastem Inc, H2 2017

Malignant Mesothelioma-Pipeline by Vyriad Inc, H2 2017

Malignant Mesothelioma-Pipeline by Y's Therapeutics Co Ltd, H2 2017

Malignant Mesothelioma-Dormant Projects, H2 2017

Malignant Mesothelioma-Dormant Projects, H2 2017 (Contd..1), H2 2017

Malignant Mesothelioma-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Aduro BioTech Inc

Advantagene Inc

AnGes MG Inc

arGEN-X BV

ArQule Inc

AVEO Pharmaceuticals Inc

Biogen Inc

Bionomics Ltd

Biotecnol Ltd

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Company

Calithera Biosciences Inc

CanBas Co Ltd

CBT Pharmaceuticals Inc

Checkpoint Therapeutics Inc

Concordia International Corp

Eagle Pharmaceuticals Inc

Eli Lilly and Company

EnGeneIC Ltd

EpiZyme Inc

F. Hoffmann-La Roche Ltd

Five Prime Therapeutics Inc

Genelux Corp

GlaxoSmithKline Plc

Horizon Pharma Plc

Inventiva

Juno Therapeutics Inc

Karyopharm Therapeutics Inc

Laboratoires Pierre Fabre SA

MacroGenics Inc

Madrigal Pharmaceuticals Inc.

MedImmune LLC

Merck & Co Inc

Merck KGaA

Millennium Pharmaceuticals Inc

MolMed SpA

Morphotek Inc

MTG Biotherapeutics Inc

Novartis AG

Ono Pharmaceutical Co Ltd

OSE Immunotherapeutics

Oxford BioMedica Plc

Pharma Mar SA

Philogen SpA

Polaris Pharmaceuticals Inc

Seattle Genetics Inc

Selecta Biosciences Inc

Sorrento Therapeutics Inc

Targovax ASA

Tesaro Inc

TRACON Pharmaceuticals Inc

TREAT U SA

UbiVac LLC

VasGene Therapeutics Inc

Verastem Inc

Vyriad Inc

Y's Therapeutics Co Ltd

Malignant Mesothelioma Therapeutic Products under Development, Key Players in Malignant Mesothelioma Therapeutics, Malignant Mesothelioma Pipeline Overview, Malignant Mesothelioma Pipeline, Malignant Mesothelioma Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com